Patientenforschung
Anmelden
Alle Studien
RekrutierungPHASE2INTERVENTIONELL

Eine Studie zu Amivantamab bei Teilnehmern mit fortgeschrittenen oder metastasierten soliden Tumoren, einschließlich nicht-kleinzelligem Lungenkrebs mit epidermalem Wachstumsfaktor-Rezeptor (EGFR)-Mutation

This research study is investigating a new way to give a treatment called amivantamab to people with a type of lung cancer known as non-small cell lung cancer that has spread. Currently, amivantamab is usually given by a drip into a vein. This study is testing a new version that can be injected under the skin. Researchers want to find out if this new injection method is effective at shrinking tumors and whether it is safe. The study focuses on patients whose lung cancer has specific genetic changes in a protein called EGFR. Some parts of the study will test amivantamab on its own, while others will look at it when given with other treatments like lazertinib, carboplatin, or pemetrexed. It's hoped that an under-the-skin injection might be more convenient for patients.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE2
Sponsor
Janssen Research & Development, LLC
Einschreibeziel
520
Starten
11. Nov 2022
Geschätzte Fertigstellung
18 Aug 2028
Karzinom, Nicht-kleinzelliges Lungenkarzinom

Worum geht es in dieser Studie?

This study is designed to explore a new way of giving an important cancer medicine called amivantamab. Amivantamab is used to treat a specific type of lung cancer, known as non-small cell lung cancer, especially when it has spread in the body. Currently, patients receive this medication through a long drip into a vein, which can be time-consuming and often requires hospital visits. This study is testing if amivantamab can be given as a simple injection under the skin instead, using a special combination that helps the body absorb the medicine more easily.

The main goals of this research are to see how effective this new under-the-skin injection is at fighting the cancer, and to make sure it's safe for patients. Different groups of patients will be involved, some receiving amivantamab on its own, and others receiving it alongside other cancer treatments. The study is particularly interested in patients whose lung cancer has specific genetic changes, called EGFR mutations, which amivantamab is designed to target.

Finding a way to give amivantamab as an under-the-skin injection could make treatment much easier and more convenient for patients, potentially reducing the need for lengthy hospital stays for infusions. This could significantly improve their quality of life while undergoing cancer treatment. The researchers will be carefully monitoring all participants to understand the benefits and any side effects of this new treatment method.

Wichtige Erkenntnisse

  • This study is for advanced non-small cell lung cancer with specific genetic changes.
  • It's testing a new, potentially more convenient, under-the-skin injection of a drug called Amivantamab.
  • The study aims to check how well the injection works and if it's safe.
  • Some patients will receive Amivantamab alone; others will get it with additional cancer drugs.
  • Participation involves regular check-ups, blood tests, and scans.
  • Sie können die Teilnahme jederzeit beenden.

Wer könnte berechtigt sein?

To join this study, you must have an advanced or spreading type of non-small cell lung cancer that doctors can't cure with surgery or radiation. Your cancer must have specific genetic changes called EGFR mutations. Different parts of the study look for slightly different types of these mutations, so your doctor will need to check your specific cancer test results.

Some parts of the study are for people who haven't had any other full-body treatment for their lung cancer yet. Other parts are for those whose cancer has gotten worse after specific previous treatments, such as osimertinib, or a combination of amivantamab and lazertinib. You must be at least 18 years old to take part, and the study is open to both men and women. If you have a type of lung cancer called squamous non-small cell lung cancer, you generally won't be able to join some specific parts of this study.

Crucially, your doctor will need to confirm your cancer's genetic changes using official lab tests. If you are already receiving amivantamab through a drip for at least 8 weeks without dose changes, you might also be eligible for a particular group within this study that is testing the new injection form.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I have non-small cell lung cancer that has spread.
  2. My cancer has specific EGFR genetic changes (my doctor can confirm this).
  3. I am at least 18 years old.
  4. I might not have had previous treatment, or my cancer progressed after specific treatments.
  5. My doctors say my cancer can't be cured by surgery or chemoradiation.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in this study, you will receive the study treatment, which is amivantamab given as an injection under the skin. Depending on which group you are in, you might also receive other medications like lazertinib, carboplatin, or pemetrexed, or blood clot prevention medicines.

You will have regular appointments for check-ups, blood tests, and scans to see how the treatment is working and to monitor your health. These visits will help the study doctors understand the effects of the treatment. The total duration of your participation will vary, but you will be monitored closely throughout the treatment period and for some time after your last dose. All procedures and study visits will be carefully explained to you by the study team.

Potenzielle Risiken und Vorteile

Taking part in a clinical trial offers the potential benefit of accessing new treatments before they are widely available. For this study, if the under-the-skin injection of amivantamab proves effective and safe, it could offer a more convenient way to receive your cancer treatment. However, as with any medical treatment, there are potential risks and side effects. Amivantamab and the other drugs used can cause various side effects, which will be fully explained by the study team. You always have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (110)

  • University of California at San Diego
    Verifizierte Postleitzahl
    La Jolla, Vereinigte Staaten· Rekrutierung
  • Universität von Kalifornien Irvine
    Verifizierte Postleitzahl
    Orange, Vereinigte Staaten· Rekrutierung
  • Stanford Cancer Institute
    Verifizierte Postleitzahl
    Stanford, Vereinigte Staaten· Rekrutierung
  • Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
    Verifizierte Postleitzahl
    Washington D.C., Vereinigte Staaten· Rekrutierung
  • Baptist Lynn Cancer Institute
    Verifizierte Postleitzahl
    Boca Raton, Vereinigte Staaten· Abgeschlossen
  • Mount Sinai Medical Center
    Verifizierte Postleitzahl
    Miami Beach, Vereinigte Staaten· Rekrutierung
  • AdventHealth
    Verifizierte Postleitzahl
    Orlando, Vereinigte Staaten· Rekrutierung
  • H. Lee Moffitt Cancer & Research Institute
    Verifizierte Postleitzahl
    Tampa, Vereinigte Staaten· Abgeschlossen
  • University of Kansas Cancer Center
    Verifizierte Postleitzahl
    Westwood, Vereinigte Staaten· Rekrutierung
  • Sidney Kimmel Cancer Center - Bayview Campus
    Verifizierte Postleitzahl
    Baltimore, Vereinigte Staaten· Rekrutierung
  • Boston Medical Center
    Verifizierte Postleitzahl
    Boston, Vereinigte Staaten· Rekrutierung
  • Washington University School of Medicine
    Verifizierte Postleitzahl
    St. Louis, Vereinigte Staaten· Rekrutierung

Häufige Fragen

What is Amivantamab?

Amivantamab is a medicine used to treat a specific type of lung cancer that has certain genetic changes. It helps to block signals that make cancer cells grow.

Why are they testing an injection under the skin?

Currently, Amivantamab is given through a vein. Researchers want to see if giving it as an injection under the skin is just as effective and safe, and potentially more convenient for patients.

What are EGFR mutations?

EGFR (Epidermal Growth Factor Receptor) mutations are specific changes in the genetic code of some cancer cells. These changes can make cancer grow and spread, and some medicines like Amivantamab are designed to target them.

Will I receive other treatments in this study?

Depending on which group you are in, you might receive Amivantamab on its own, or combined with other medications like Lazertinib, Carboplatin, or Pemetrexed. Your doctor will explain your specific treatment plan.

Kann ich die Teilnahme an der Studie beenden, wenn ich möchte?

Yes, you are free to leave the study at any time, for any reason, without it affecting your future medical care.

Wie Sie mehr erfahren können

Studienkontakt

participate-in-this-study1@its.jnj.com 844-434-4210 Offizielles Gerichtsprotokoll

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study of Amivantamab in Participants With Advanced or Meta… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.